“…Consistent with a previous study (Protze et al, 2017), compared with CON cardiomyocytes, hiPSC-CMs in the CDH5 group exhibited higher levels of pacemaker channel genes (HCN1, HCN4, and KCNJ3). Suppressing the endogenous inward rectifier potassium current (I K1 ) was first used to create biological pacemaker via gene therapy (Cingolani et al, 2018) In contrast to prior investigations (Gharibeh et al, 2021;Liu et al, 2020;Protze et al, 2017;Wang et al, 2023;Yin et al, 2022;Zhang et al, 2022;Zhao, Wang, et al, 2020), our approach to procuring SANLPCs exhibits superior attributes in terms of simplicity, controllability, and cost-effectiveness. However, in relation to the final proportion of acquired SANLPCs, our study did not present a notable advantage compared with previous research (Liang et al, 2020;Ren et al, 2019).…”